TY - JOUR
T1 - Risk scores for type 2 diabetes mellitus in Latin America
T2 - a systematic review of population-based studies
AU - Carrillo-Larco, R. M.
AU - Aparcana-Granda, D. J.
AU - Mejia, J. R.
AU - Barengo, N. C.
AU - Bernabe-Ortiz, A.
N1 - Funding Information:
Strategic Award, Wellcome Trust-Imperial College Centre for Global Health Research (100693/Z/12/Z). Imperial College London Wellcome Trust Institutional Strategic Support Fund [Global Health Clinical Research Training Fellowship] (294834/Z/16/Z ISSF ICL). Rodrigo M Carrillo-Larco is supported by a Wellcome Trust International Training Fellowship (214185/Z/18/Z). The funder had no role in the conception of this work, neither in the preparation or presentation of results. The authors are responsible for the results and opinions in this work.
Publisher Copyright:
© 2019 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Aim: To summarize the evidence on diabetes risk scores for Latin American populations. Methods: A systematic review was conducted (CRD42019122306) looking for diagnostic and prognostic models for type 2 diabetes mellitus among randomly selected adults in Latin America. Five databases (LILACS, Scopus, MEDLINE, Embase and Global Health) were searched. type 2 diabetes mellitus was defined using at least one blood biomarker and the reports needed to include information on the development and/or validation of a multivariable regression model. Risk of bias was assessed using the PROBAST guidelines. Results: Of the 1500 reports identified, 11 were studied in detail and five were included in the qualitative analysis. Two reports were from Mexico, two from Peru and one from Brazil. The number of diabetes cases varied from 48 to 207 in the derivations models, and between 29 and 582 in the validation models. The most common predictors were age, waist circumference and family history of diabetes, and only one study used oral glucose tolerance test as the outcome. The discrimination performance across studies was ~ 70% (range: 66–72%) as per the area under the receiving-operator curve, the highest metric was always the negative predictive value. Sensitivity was always higher than specificity. Conclusion: There is no evidence to support the use of one risk score throughout Latin America. The development, validation and implementation of risk scores should be a research and public health priority in Latin America to improve type 2 diabetes mellitus screening and prevention.
AB - Aim: To summarize the evidence on diabetes risk scores for Latin American populations. Methods: A systematic review was conducted (CRD42019122306) looking for diagnostic and prognostic models for type 2 diabetes mellitus among randomly selected adults in Latin America. Five databases (LILACS, Scopus, MEDLINE, Embase and Global Health) were searched. type 2 diabetes mellitus was defined using at least one blood biomarker and the reports needed to include information on the development and/or validation of a multivariable regression model. Risk of bias was assessed using the PROBAST guidelines. Results: Of the 1500 reports identified, 11 were studied in detail and five were included in the qualitative analysis. Two reports were from Mexico, two from Peru and one from Brazil. The number of diabetes cases varied from 48 to 207 in the derivations models, and between 29 and 582 in the validation models. The most common predictors were age, waist circumference and family history of diabetes, and only one study used oral glucose tolerance test as the outcome. The discrimination performance across studies was ~ 70% (range: 66–72%) as per the area under the receiving-operator curve, the highest metric was always the negative predictive value. Sensitivity was always higher than specificity. Conclusion: There is no evidence to support the use of one risk score throughout Latin America. The development, validation and implementation of risk scores should be a research and public health priority in Latin America to improve type 2 diabetes mellitus screening and prevention.
UR - http://www.scopus.com/inward/record.url?scp=85071891275&partnerID=8YFLogxK
U2 - 10.1111/dme.14114
DO - 10.1111/dme.14114
M3 - Review article
C2 - 31441090
AN - SCOPUS:85071891275
SN - 0742-3071
VL - 36
SP - 1573
EP - 1584
JO - Diabetic Medicine
JF - Diabetic Medicine
IS - 12
ER -